ARTICLE | Company News
Chiesi, Cornerstone Therapeutics sales and marketing update
August 10, 2009 7:00 AM UTC
The companies closed a previously announced deal that gave Chiesi a 51% stake in Cornerstone and gave Cornerstone exclusive rights to market Chiesi's Curosurf poractant alfa in the U.S. for 10 years ...